HER-2/neu expression as a predictive factor for response to anthracycline-based chemotherapy in a Mexican Population of locally advanced breast cancer patients

By Muñoz-Gonzalez David   Zeichner-Gancz Isabel   Candelaria Myrna   Ramirez-Ugalde Maria   Perez-Sanchez Manuel   Cervantes-Vazquez Guadalupe   Cantu-de Leon David   Mora-Tizcareño Arcelia   Leonor-Ortíz Julio  

Medical Oncology, Vol. 22, Iss. 1, 2005-03 ,pp. : 23-28

Humana Press, Inc

Access to resources Recommend Favorite

Biological considerations in locally advanced breast cancer treated with anthracycline-based neoadjuvant chemotherapy: thymidine labelling index is an independent indicator of clinical outcome

By Ozmen V.  

Breast Cancer Research and Treatment, Vol. 68, Iss. 2, 2001-07 ,pp. : 147-157

Springer Publishing Company

Access to resources Recommend Favorite

ERBB2 overexpression in breast carcinomas - no positive correlation with complete pathological response to preoperative high-dose anthracycline-based chemotherapy

By Vincent-Salomon A.   Carton M.   Freneaux P.   Palangie T.   Beuzeboc P.   Mouret E.   de Cremoux P.   Coue O.   Zafrani B.   Nicolas A.   Clough K.   Fourquet A.   Pouillart P.   Sastre-Garau X.  

European Journal of Cancer, Vol. 36, Iss. 5, 2000-03 ,pp. : 586-591

Elsevier

Access to resources Recommend Favorite

Clinical and pathological predictors of the response to neoadjuvant anthracycline chemotherapy in locally advanced breast cancer

By Fernández-Sánchez Mónica   Gamboa-Dominguez Armando   Uribe Norma   García-Ulloa Ana   Flores-Estrada Diana   Candelaria Myrna   Arrieta Oscar  

Medical Oncology, Vol. 23, Iss. 2, 2006-06 ,pp. : 171-183

Humana Press, Inc

Access to resources Recommend Favorite

Economic Analyses of Toxicity Secondary to Anthracycline-based Breast Cancer Chemotherapy

By Dranitsaris G.   Tran T.M.  

European Journal of Cancer, Vol. 31, Iss. 13, 1995-12 ,pp. : 2174-2180

Elsevier

Access to resources Recommend Favorite